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1.1. HIV infection: history, definition and modes of 
transmission  
 
The earliest reports of a new disease were seen in the late 
seventies-early eighties, after observing rare opportunistic 
diseases such as Kaposi Sarcoma or Pneumocystis carinii 
pneumonia, usually occurring in immunodeprimed people, in 
a cluster of intravenous drug users and gay men in the United 
States. The syndrome was called AIDS, Acquired 
Immunodeficiency Syndrome. In Africa, AIDS was first seen in 
1982 in Uganda, and shortly after in other countries of the 
continent. In 1983, scientists from independent research 
groups in the United States (Gallo et al.) and in France (Barre-
Sinoussi et al.) discovered the virus that causes AIDS [1,2]. The 
virus was at first named HTLV-III/LAV (human T-cell 
lymphotropic virus-type III/lymphadenopathy-associated 
virus) and later renamed to HIV (human immunodeficiency 
virus). 
The HIV virus belongs to the Retroviridae family. The 
classification is done by phylogenetic analysis and nucleotidic 
sequencing of the viruses. It consists of two types, several 
groups, subtypes and sub-subtypes (Figure 1).  
 12 
 
  
Figure 1. HIV classification. RF – Recombinant Form 
 
HIV-1 subtype C is dominating the HIV epidemic. HIV-1 
subtype B is in general more prevalent in Europe and the 
Americas, while subtypes C, A and D are mainly found in sub-
Saharan Africa. However, there is diversity, with presence of 
many recombinant forms (Figure 2) [3]. The HIV-2 virus is less 
virulent and was initially found in West-Africa. 
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Figure 2. Map of HIV-1 groups and subtypes. CRF Circulating Recombinant Form; URF 
Unique Recombinant Form 
 
Horizontal transmission of HIV can be parenteral transmission 
(contaminated blood transfusion (including blood transfusion 
during the diagnostic window period), needle sharing during 
intravenous drug use, percutaneous infection (needle, cutting 
objects with contaminated blood)) or sexual transmission 
(unprotected sexual contact).  
Vertical transmission of HIV occurs from mother to child (in 
utero, during delivery and through breast milk). This 
transmission mode will be discussed in more detail in section 
1.2.2. 
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1.2. HIV and mother-to-child transmission globally  
 
1.2.1. Epidemiology  
 
By the end of 2013, an estimated 35 million people were living 
with HIV globally, including 16 million women [4]. One eighth 
of those women are aged between 15 and 25 years. An estimated 
1.5 million women living with HIV gave birth in the same year. 
About 3.3 million children <15 years were living with HIV/AIDS 
globally by December 2013; 2.9 million of them living in sub-
Saharan Africa [4].  
 
Worldwide, about 2.1 million people were newly infected in the 
year 2013, a 35% reduction of new infections than those 
observed in 2009. One and a half million of those occurred in 
sub-Saharan Africa [4]. An estimated 700 children younger 
than 15 years are infected daily with HIV, giving a number of 
240,000 newly infected children in 2013. The majority of these 
infections occurs through vertical transmission [4].  
In 2012, the under-five mortality rate was 48/1000 live births 
globally; in low income countries it was 82/1000 live births. 
Malaria, pneumonia, diarrhoea and neonatal disorders are the 
main causes of death in children under five globally [5]. HIV is 
the cause of death in 2% of the deaths among children under 
five years of age in low income countries [6]. Without 
treatment, up to 52% of children infected with HIV will die 
before their second birthday, compared to 8% in HIV-exposed 
uninfected children [7]. Prophylaxis with cotrimoxazole is 
given to all HIV-exposed infants to decrease risk of respiratory 
and gastrointestinal infections.  
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Prevention of mother-to-child transmission of HIV is key to 
reduce infant mortality and morbidity. With the introduction 
of HIV screening in pregnant women, and the use of 
antiretroviral drugs, the HIV transmission rate reduced with 
43% between 2009 and 2013 [8]. 
 
1.2.2. Mother-to-child transmission of HIV 
 
Mother-to-child transmission is defined by WHO as: “HIV 
infection transmitted from an HIV-infected mother to her child 
during pregnancy, labour, delivery or breastfeeding”. 
 
Timing and risk of transmission  
Vertical transmission of HIV can occur during pregnancy (in 
utero), during labour and delivery, or during breastfeeding. 
Without any intervention, 5-10% of the infants are infected 
through transmission during pregnancy, 10-20% during labour 
and delivery and 5-20% during breastfeeding, resulting in a 
total risk of up to 45% [9].  
Risk factors for vertical transmission are related to the mother, 
the child or the HIV virus itself, and are presented in table 1. 
The mothers’ clinical and immunological status during 
pregnancy are important as risk factors, where low CD4+ T-cell 
count and advanced stage are associated with an increased risk 
for vertical transmission [10]. A higher viral load is associated 
with a higher risk of transmission [11]. As the viral load is high 
after acute infection, the vertical transmission rate among 
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women who acquired HIV infection postnatally has been seen 
to be as high as 36% [12-14]. 
Exclusive breastfeeding in the first six months of life has been 
proven to be one of the main protectors of child morbidity and 
mortality [15,16]. It provides an ideal food for the growth and 
development of infants and protects against respiratory 
infections and diarrhoea [17-19]. However, in 2012, only about 
37% of the infants are exclusively breastfed for the first six 
months of life globally [6]. Preference of mixed feeding, lack of 
skilled support and lack of knowledge of the consequences of 
non-exclusive breastfeeding play a role to these low rates [20]. 
The risk of transmission of HIV through breastmilk needs to 
be weighed against the risk of malnutrition or other infections 
[21]. Infants who received mixed breastfeeding are shown to be 
at higher risk of HIV acquisition compared to those who were 
exclusively breastfed [22,23]. The Mashi trial showed that HIV 
transmission at seven months was higher in breastfed infants, 
but that the mortality was lower than in non-breastfed infants, 
so overall HIV free survival did not differ at 18 months [24].  
The WHO guidelines on HIV and infant feeding recommend 
exclusive breastfeeding until the age of six months, and 
thereafter continue breastfeeding (aside the introduction of 
solid food) unless conditions are available to stop safely. 
Where antiretroviral therapy is available, breastfeeding should 
be continued after six months [25].  
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Table 1. Risk factors for vertical transmission of HIV 
Mother  High maternal viral load 
Advanced disease, mastitis 
Low CD+4 T-cell count 
Prolonged rupture of membranes 
Presence of other sexually transmitted infections 
Vaginal delivery 
Child  Prematurity 
Breastfeeding 
Genetic factors 
Oral thrush 
Virus Subtype (subtype C) 
Adapted from Newell [11] and Mofenson [26] 
 
Prevention of mother-to-child transmission of HIV (PMTCT) 
The WHO promotes a comprehensive approach to prevent 
mother-to-child transmission, consisting of four prongs 
including primary and secondary prevention [27]:  
1. Primary prevention of HIV infection among women of 
childbearing age 
2. Preventing unintended pregnancies among women living 
with HIV 
3. Preventing HIV transmission from a woman living with 
HIV to her infant 
4. Providing appropriate treatment, care and support to 
mothers living with HIV and their children and families 
The Global Plan towards the Elimination of new HIV infections 
among children by 2015 and keeping their mothers alive was 
elaborated by UNAIDS in 2011 and sets clear targets and 
 18 
 
indicators (Figure 3, [28]), prioritizing 22 countries1. The global 
goal is “To accelerate progress towards the elimination of new 
child infections by 2015 and keeping their mothers alive”, with 
2 global targets:  
1) Reduce the number of new childhood HIV infections by 
90% 
2) Reduce the number of HIV-related maternal deaths by 
50% 
The target of reducing new childhood HIV infections by 90% 
reflects the contributions of the four-pronged strategy for 
preventing the mother-to-child transmission of HIV and 
signifies the importance of a comprehensive approach. 
 
Figure 3. Targets and Indicators to achieve Elimination of Paediatric HIV by 2015 (UNAIDS)  
                                                          
1 The Global Plan prioritized 22 countries where 90% of pregnant women living with HIV resided: Angola, 
Botswana, Burundi, Cameroon, Chad, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Ghana, 
India, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, South Africa, Swaziland, Uganda, United 
Republic of Tanzania, Zambia and Zimbabwe.  
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Most emphasis has been given to the prophylaxis with 
antiretroviral drugs, with rapid evolvement and good progress 
(prong 3). However, modelling analyses show that combined 
interventions where all four prongs are addressed are needed 
to achieve on elimination of paediatric HIV, with a calculated 
reduction of new HIV infections of 79% and a vertical 
transmission rate of 8% [29,30]. 
Prong 1 has lagged behind with implementation of specific 
prevention services for women of reproductive age. In 2013, 
about 44% of pregnant women received an HIV test, a key for 
access to prevention and treatment of HIV [4]. Data on HIV 
incidence among pregnant an breastfeeding have been 
presented and vary in different African settings from 2.3/100 
women-years in Uganda [31], to 10.7/100 women-years in 
South-Africa [32]. The need to address seroconverters has 
grown as the risk for vertical transmission is higher [11].  
Access to family planning is crucial for HIV-positive women, 
and contributes to prevention of vertical transmission (prong 
2) [33]. However, the unmet need for contraception is still high 
(29% in the 21 priority countries in 2013 [8] and needs to be 
addressed [34]. A review by Wilcher et al. describes that there 
are many factors for not opting to have more children among 
women living with HIV, such as fear for transmission, stigma, 
lack of knowledge of the benefits of the treatment, current 
health status, etc. Factors associated with the desire for having 
children include having no or few children, partners’ desire, 
short period of marriage [34].  
Most progress was seen in the provision of antiretroviral drugs 
to prevent vertical transmission of HIV (prong 3). A major 
breakthrough in prevention occurred in 1994: the Pediatric 
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AIDS Clinical Trials Group (PACTG) protocol 076 showed that 
zidovudine (ZDV) given during pregnancy and the first six 
weeks postpartum period reduced perinatal transmission by 
two thirds in a non-breastfeeding population [35]. Combined 
with caesarean section and bottle feeding, the transmission 
can be reduced to 2% [36,37]. In the decade 2000, shorter 
course combination regimens of antiretroviral drugs were 
introduced [38-41]. The HIVNET012 trial in Uganda, using 
single-dose Nevirapine (NVP) given at the onset of labour and 
to the newborn, reduced HIV transmission at 14-16 weeks by 
47% compared to zidovudine [42]. Nevirapine has very few side 
effects compared to other drugs such as zidovudine, a drug 
widely used in the PMTCT regimens, and possibly leading to 
anaemia and neutropenia. While having an effective and easy 
short regimen, the risk of antiretroviral drug resistance using 
single drug nevirapine was up to 38% in mothers and 53% in 
infants [43]. Factors associated with development of resistance 
include HIV-subtype, CD4+ T-cell count, viral load, 
compartment (plasma, breastmilk), and number of doses) [44-
47]. Another challenge is the failure of protection during 
breastfeeding if no drugs are offered.  
Several trials done in Africa evaluating postnatal infant 
prophylaxis have shown a reduction in HIV transmission and 
seemed to be safe and effective in reducing HIV transmission 
(table 2) [48,49]. In a comparison study of three trials (PEPI 
(“Post-Exposure Prophylaxis of Infants”), BAN (“Breastfeeding, 
Antiretrovirals, and Nutrition”), SWEN (“Six Weeks Extended 
Nevirapine”)), it was also shown that a longer period of 
postnatal prophylaxis was more protective [50]. The HIV 
Prevention Trials Network (HPTN046), where infant 
prophylaxis with nevirapine was given during the first six 
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months, showed a superior protection at 6 months 
(transmission rate of 1.1% among infants receiving nevirapine 
group versus 2.4% among infants receiving placebo, p=0.02). 
No significant difference was seen at 18 months, showing that 
among breastfeeding women the efficacy is lost once drugs are 
stopped [51,52]. Recent studies using triple antiretroviral 
therapy for HIV positive women who do not need treatment 
for their own health showed to be efficacious in the reduction 
of infant HIV transmission and death (table 3). Highly active 
antiretroviral therapy reduces vertical transmission risk to less 
than 1% [53,54].  
The Kesho-Bora study showed a superior efficacy of 
antiretroviral treatment versus a short regimen among 
breastfeeding women (cumulative HIV transmission rate at 12 
months 5.6% versus 10.7%, p=0.02) [55].  
Table 2. MTCT risk using extended infant prophylaxis 
Trial  Regimen 
mother 
Regimen Infant MTCT risk  
SIMBA (Rwanda, 
Uganda)[56] 
AZT+ddI 36 
weeks of 
gestation to 1 
week postpartum 
Daily NVP or 
daily 3TC from 
birth up to 6 
months 
7.7% at 6 
months 
MASHI 
(Botswana)[24] 
AZT+single dose 
NVP 34 weeks of 
gestation to 1 
week postpartum 
Daily AZT from 
birth up to 6 
months (+ 
breastfeeding) 
9.0% at 7 
months 
MITRA 
(Tanzania)[57] 
AZT+3TC 36 
weeks of 
gestation to 1 
week postpartum 
Daily 3TC from 
birth up to 6 
months 
8.5% at  6 
months 
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Adapted from WHO PMTCT guidelines [62]  
 
 
Table 3. MTCT risk using antiretroviral therapy in women who do not need for their own 
health 
Trial  Regimen mother Duration MTCT risk  
KIBS (“Kisumu 
Breastfeeding 
Study”) 
(Kenya)[63] 
CD4>250 
AZT+3TC+NVP 
sdNVP for infant 
34 weeks 
gestational age 
up to 6 months 
postpartum 
Among women 
with CD4≥250: 
4.9% at 6m 
Kesho Bora 
(Burkina Faso, 
Kenya, South 
Africa) [55] 
CD4 200-500 
AZT+3TC+LPV/r 
sdNVP + AZT 1 week 
for infant 
From 28-36 
weeks 
gestational age 
until 6 months 
postpartum 
Among women w 
CD4 200-500: 
4.9% at 6m 
PEPI (Malawi)[58] Single dose NVP 
at onset of labour  
Daily NVP or 
NVP/AZT from 
birth up to 14 
weeks 
Among infants 
HIV uninfected 
at birth – NVP  
5.9% at 9 
months; 6.4% 
NVP/AZT 
SWEN (Ethiopia, 
Uganda, India)[59] 
Single dose NVP 
at onset of labour  
Daily NVP or 
NVP/AZT from 
birth up to 6 
weeks 
Among infants 
HIV uninfected 
at birth 6.9 % at 
6 months 
BAN 
(Malawi)[60,61] 
Single dose NVP 
at onset of labour 
+ AZT+3TC 
during labour + 1 
week postpartum 
Daily NVP from 
birth up to 6 
months 
Among infants 
HIV uninfected 
at age of 2 
weeks 1.7% at 
6.5 months 
HPTN046 (South 
Africa, Tanzania, 
Uganda, 
Zimbabwe) [51]  
Any PMTCT or 
lifelong ART 
Daily NVP from 
birth up to 6 
months 
Among infant 
HIV uninfected 
at age of 6 
weeks: 1.1% at 6 
months  
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AMATA 
(Rwanda) [64] 
CD4<350: 
d4T+3TC+NPV 
CD4>350: 
AZT+3TC+EFV 
sdNVP + AZT 1 week 
infant 
From 28 weeks 
gestational age 
until 7 months 
postpartum 
Stop 
breastfeeding at 
6 months 
Overall 1.9% at 9 
months 
MITRA-PLUS 
(Tanzania)[65] 
All women 
AZT+3TC+NVP 
From 3 weeks 
gestational age 
until 6 months 
postpartum. 
Continued if 
eligible  
Women with 
CD4>200 5.3% at 6 
months 
DREAM cohort 
(Mozambique) 
[54] 
All women 
AZT+3TC+NVP 
Sd NPV for infant  
From 15 weeks of 
gestational age 
2.2% at 6 months 
Mma Bana 
(Botswana)[66] 
CD4>200: 
ABC+AZT+3TC or 
AZT+3TC+LPV7r 
From 26 to 34 
weeks of 
gestational age 
until 6 months 
postpartum 
Among women 
with CD4>200: 
1.1% at 6 months 
BAN 
(Malawi)[60,61] 
CD4>250: 
AZT+3TC+LPV/r 
From labour 
until 6 months 
postpartum 
Among women 
with CD4>250: 
2.9% at 6 months 
in infants un-
infected at 2 weeks 
Adapted from WHO PMTCT guidelines [62] 
The WHO guidelines on PMTCT antiretroviral 
recommendations evolved over the last 12 years as more data 
became available, and taking into account feasibility and 
affordability in resource limited settings (table 4). Currently, 
the WHO recommends lifelong treatment for all HIV positive 
pregnant women (“Option B+”) [49].  
 
 
 24 
 
Table 4. Guidelines for antiretroviral prophylaxis and treatment according to the WHO 
Guidelines (2001-2013) 
 
a Option A: Woman receives ZDV from 14wks + single dose NVP intrapartum + ZDV/3TC 
from intrapartum for 7 days. Infant receives daily NVP until 7 days after cessation of 
breastfeeding 
b Option B: Woman: triple antiretroviral prophylaxis starting from as early as 14 weeks of 
gestation and continued until delivery, or, if breastfeeding, continued until 1 week after all 
infant exposure to breast milk has ended. Infant receives daily NVP or twice daily ZDV from 
birth until 4 to 6 weeks of age. 
c Option B+: Woman: lifelong triple antiretroviral as early as 14 weeks of gestation. Infant 
receives daily NVP or twice daily ZDV from birth until 4 to 6 weeks of age. 
 
Although progress on the provision of ongoing care and 
treatment for families (women and their HIV-infected or HIV-
exposed children) was made (prong 4), uptake and retention 
to these services remain a problem. Despite an increase of the 
 
2001 
[67,68] 
2004 [69] 2006 [70] 2010 [62]  2013 [49] 
P
M
T
C
T
 
Short 
regimen for 
mother and 
infant using:  
 
ZDV 
OR 
ZDV/3TC 
OR  
single NVP  
Woman: ZDV 
from 28 weeks 
+ single NVP 
intrapartum 
 
 
 
 
 
Infant: single 
dose NVP + 
ZDV for 7 
days 
Woman: ZDV 
from 28 weeks 
+ single dose 
NVP 
intrapartum + 
ZDV/3TC from 
intrapartum 
for 7 days 
 
Infant: single 
dose NVP + 
ZDV for 7 days  
Infant 
prophylaxis 
(Option 
Aa)  
 
OR 
 
Maternal 
ART  
(Option Bb)  
Maternal 
ART  
(Option Bb) 
 
 
OR 
 
Lifelong 
maternal 
ART  
(Option 
B+c) 
L
IF
E
L
O
N
G
 A
R
T
 
No 
recommend
ation 
CD4 <200 CD4 <200 CD4 <350 
CD4 <500 
(if Option 
B) 
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worldwide coverage of PMTCT antiretroviral services from 33% 
in 2009 to 68% in 2013 [8], adherence to treatment among 
women who have access is estimated at 75% and is worse 
during the postpartum period [71]. Data on adherence among 
pregnant women who initiated lifelong ART (Option B+) show 
a lost to follow-up of 17% [72]. In a review, a pooled proportion 
of 49% loss to follow-up was seen during antenatal care, 34% 
from delivery to three months postpartum and 46% after infant 
HIV testing [73].  
Integration of HIV services within mother and child health 
(MCH) services has been promoted to increase access to 
prevention services and to treatment for HIV positive women. 
In the last UNAIDS progress report (2013), 79 (67%) countries 
reported having many facilities where HIV counselling and 
testing are integrated within MCH services, and 83 (70%) 
countries reported having a high number of facilities with HIV 
care to prevent mother-to-child transmission integrated 
within MCH services[4]. 
HIV positive pregnant women with a low CD4+ T-cell count 
have a higher risk for HIV-transmission [10]; during the 
breastfeeding period being 3-10 times higher when immunity 
is low [74,75]. CD4+ T-cell count testing has been crucial to 
determine eligibility for antiretroviral therapy before the 
introduction of Option B+ strategy. Resource-limited settings 
do not always have the capacity or resources to perform the 
analysis in all health facilities as they are usually referred to the 
higher level laboratory. Point-of-care testing for CD4+ T-cell 
enumeration has been shown to be accurate and feasible 
among non-pregnant adults in several African settings [76-78], 
and give reliable results in pregnant women [79]. With the 
recent introduction of point-of-care testing, results are 
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immediately available. It is expected to have less loss to follow 
up, as no return visit is needed to receive results [80,81]. 
However, most data on results of effectiveness are available for 
non-pregnant populations, and results on the PMTCT 
programs are scarce. 
Closing the PMTCT cycle occurs at final diagnosis of HIV status 
of the HIV-exposed infants. Early infant diagnosis using dried 
blood spots to detect HIV infection through DNA-PCR analysis 
is implemented in many countries, and crucial for early 
diagnosis and referral for prompt care and treatment. In 2013, 
only 42% of infants born to mothers living with HIV in low- 
and middle-income countries received an HIV test in the first 
two months after delivery [4].  
Early treatment of HIV positive children was proven to be 
superior to deferred treatment in the CHER (“Children with 
HIV Early antiretroviral”) trial, with a reduction of mortality 
rate by 75% when antiretroviral treatment was given before the 
age of 12 weeks [82]. The 2013 WHO guidelines recommend 
antiretroviral therapy for all HIV-infected children under five, 
independent of clinical or immunological staging; and for all 
children older than 5 years when the CD4+ T-cell count <500 
cells/µL, WHO stage 3/ 4  or active tuberculosis [49]. However, 
only 22% of children living with HIV are receiving treatment in 
the 21 priority countries [8].  Adherence to HIV prevention and 
care services for HIV-exposed (until final diagnosis) and HIV 
infected children (with immediate treatment) is crucial for 
survival, and innovative approaches may be needed to reduce 
current levels of patient attrition. 
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1.3. HIV and mother-to-child transmission in 
Mozambique 
 
The first case of AIDS in Mozambique was diagnosed in the 
northern province Cabo Delgado in 1986. Since 1988, ANC 
surveillance sites were established to monitor the HIV 
prevalence, initially in one health post in Maputo city, but 
gradually expanding to a current number of 36 sentinel sites 
located in the whole country.  
 
1.3.1. HIV epidemic in Mozambique 
 
In 2011, almost three million people in Mozambique were 
tested for HIV, the majority at MCH services. Various health 
care services provide counselling and testing for HIV, such as: 
laboratories, blood banks, adolescents and youth clinics, 
tuberculosis clinics, MCH clinics, counselling and testing units 
and community counselling and testing services [83]. 
 
Mozambique accounts for six percent of the total HIV burden 
[4]. It is estimated that nearly 1.6 million Mozambicans are 
living with HIV; 200,000 are children less than 15 years of age. 
Around 120,000 new infections occurred in 2012, 14,000 under 
15 years of age [4]. In the adult age group (15-49 years), women 
are disproportionately affected by HIV infection compared to 
men: HIV prevalence among women is 13.1% compared to 9.2% 
among men [84]. The most recent epidemiological surveillance 
data show that HIV prevalence among pregnant women in 
Mozambique is 15.8% in 2011 [85]. The evolution 2001-2011 is 
presented in Figure 4 [85,86].  
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Figure 4. HIV prevalence among pregnant women attending antenatal care, 
Mozambique (2001-2011)  
 
The mortality of infants 0- 1 year old in Mozambique is 
estimated at 64/1000 in 2011; neonatal mortality (0-1 month) at 
30/1000 [87]. During neonatal period, the three main causes of 
death are prematurity, perinatal asphyxia and new-born sepsis  
[88]. The impact of HIV on child mortality in Mozambique is 
high: 11% of the deaths between 1-12 months are caused by HIV, 
being one of the three main causes in that age group (malaria 
and diarrhoea are the two other main causes) [88]; in children 
under the age of five years, it is estimated at 6% [6]. 
In a study done in 2009 in Southern Mozambique, mortality 7-
29 days was higher in HIV-positive mothers compared to HIV-
negative mothers (7.8% versus 1.9%, p<0.001) [89].  
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HIV diagnosis in Mozambique  
The Mozambique national HIV guidelines (2013) include both 
client and provider initiated HIV testing. At antenatal care, the 
“opt-out” strategy is used (provider initiated), where all women 
are routinely offered HIV testing at their first antenatal care 
visit. Retesting is done when the last test was done more than 
3 months ago. All services at MCH offer HIV counselling and 
testing [90].  
The national programs’ guideline on HIV testing is a serial 
algorithm of two rapid tests. An individual is considered HIV 
negative when the first test (Determine HIV1/2) is non-
reactive. When this first test is reactive, a second test (Unigold 
Recombigen) is performed for confirmation. An individual is 
considered to be HIV-positive when both tests are reactive. If 
the second test is non-reactive, then the individual is 
considered to be indeterminate cases and is asked to return for 
retesting four weeks later [90].  
 
HIV care and treatment services  
Once diagnosed HIV positive, clinical and immunological 
staging is done. Enumeration of CD4+ T-cell count is done 
either by referring blood samples to the district or provincial 
reference lab on fixed days a week (one or two), or by point-
of-care testing at the health facilities’ laboratory.  
Other minimal laboratory testing is haemoglobin. Following 
the eligibility criteria of the 2013 guideline (table 5), 
antiretroviral therapy is started or monitoring of the patient is 
done until eligible.  
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Table 5. Criteria for antiretroviral therapy initiation in Mozambique 
After preparation of patient to guarantee adherence:  
Clinical Stage  CD4 available  CD4 not available  
I Initiation of treatment when CD4 
≤350 cells/µL 
No treatment 
II 
III Initiation of treatment 
independently of CD4 
Treatment initiation 
IV 
Special groups:  
All children aged < 5years with confirmed diagnosis should start ART 
independently of clinical and immunological staging 
All pregnant and breastfeeding HIV positive women should start ART 
independently of clinical and immunological staging 
All patients diagnosed with HIV-Hepatitis B and HIV-HTLV should start ART 
independently of clinical and immunological staging 
All patients diagnosed with HIV and TB should start ART independently of 
immunological staging 
All patients with (any) invasive cancer and HIV should start ART independently 
of any other condition 
All partners of HIV positive pregnant or breastfeeding women who are HIV 
negative 
Source: MOH Guideline of antiretroviral therapy and opportunistic infections in adults, 
adolescents, children and pregnant women [90] 
 
1.3.2. PMTCT program in Mozambique 
 
Mozambique was declared one of the 22 priority countries in 
the Global Plan of Elimination of Paediatric HIV [28]. The 
national program for prevention of mother to child 
transmission was initiated in 2002 in eight health facilities 
(HF), but knew a rapid scale up, as shown in Figure 5. A 
National Acceleration Plan was approved in 2013, with the 
adoption of the latest WHO recommendations.  The plan 
includes the following actions: further scale up of antiretroviral 
therapy; introduction of the use of tenofovir in the 
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antiretroviral drug regimen; three-monthly drug dispensing 
(instead of monthly); implementation of Option B+ for 
PMTCT; “One-stop” model2 in mother and child health and 
tuberculosis services; task-shifting for antiretiroviral therapy 
provision. 
 
 
Figure 5. Scale up PMTCT program in Mozambique (2002-2013) 
 
 
 
 
 
                                                          
2 In the one-stop model, the MCH clinic visit for the mother and HIV-exposed child is integrated: all 
MCH and HIV services are offered in the same room, including prophylaxis for infant and ART for mother. 
2002
• Initiation of PMTCT program in 8 health facilities
• Recommended regimen: single dose nevirapine
2004
• PMTCT as a national program
2006
• Integration of PMTCT in MCH services
• Recommended regimen: zidovudine initiating at 28 weeks of 
gestational age + nevirapine single dose
2010
• Introduction of Early Infant Diagnosis (DNA-PCR for HIV using 
Dried Blood Spots (DBS))
• Universal ART for HIV-infected infants less than two years of age
• Recommended regimen: Option A
2013
• Acceleration Plan of expansion of Antiretroviral Therapy
• Recommended regimen: Option B+ 
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A total of 1250 HF provided PMTCT services in 2014, with 1120 
offering dried blood spot sample collection for early infant 
diagnosis (EID) (MOH – national PMTCT meeting, February 
2015). By December 2014, 2575 MCH nurses had been trained 
on Option B+ and 743 HF in the country were providing Option 
B+. 
 
 
1.3.3. Mother and child care services and HIV in 
Mozambique 
 
The MCH services are well defined by the Ministry of Health. 
Routine antenatal care services include a minimum of four 
antenatal care visits.  Coverage of first antenatal care visit is 
91%, but women arrive late: the median gestational age at first 
antenatal visit is 24 weeks [87]. 
Standard MCH services for all pregnant women attending the 
first antenatal consultation include laboratory screening for 
anaemia and syphilis, and HIV counselling and testing, as per 
national protocol. Partners are verbally invited for HIV testing. 
Repeat testing for anaemia is advised at 36 weeks of gestational 
age. All pregnant women receive a bed net free of charge, 
tetanus vaccination, and prophylactic treatment for malaria 
(Sulfadoxine/pyrimethamine), parasite infection 
(mebendazole) and multivitamins/micronutrients 
supplements as part of the routine care. Health facility delivery 
is recommended during antenatal care visits, such as 
counselling on infant feeding options.  
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Routine care during the postpartum period consists of a visit 
at seven days postpartum for mother and child and a visit at 
two months, the time when family planning is offered. Infants 
are vaccinated for tuberculosis (BCG vaccine) at delivery. 
Vaccination visits for infants are planned at 2, 3, 4, 6 and 9 
months after delivery (table 6). The national norm 
recommends a monthly visit to the well-child clinic until one 
year of age, a quarterly visit in the second year of life, and a six-
monthly visit until the age of five years.  
This includes a clinical check-up of the infant and the 
monitoring of psychomotor development (milestones), growth 
and weight.  
 
Table 6. Immunization Schedule for infants in Mozambique (2015) 
Age Antigen 
Birth BCG, OPV0 
2 months DTP-HepB+Hib1, OPV1, PCV1, Rota 
3 months DTP-HepB+Hib2, OPV2, PCV2, Rota 
4 months DTP-HepB+Hib3, OPV3, PCV3 
9 months Measles 
Source: MOH, Extended Program for Immunization. DTP: Diphtheria-Tetanus-Pertussis; 
HepB: Hepatitis B; HiB: Haemophilus Influenza type B; OPV: Oral Polio Vaccine; PCV: 
Pneumococcus Vaccine; Rota: Rotavirus Vaccine. DTP-HepB-Hib vaccination are given in one 
injection, known as the “pentavalent” vaccine.  
 
Currently, HIV care is integrated in MCH services. All HIV-
infected pregnant women are eligible for antiretroviral 
treatment (ART) as per the current national guidelines (Option 
B+, 2013). Analysis for CD+4 T-cell count is not further needed 
to define eligibility for ART, but is still recommended for 
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monitoring of treatment, since viral load is unavailable.  Prior 
to ART initiation, women are expected to receive pre-ART 
adherence counselling sessions. Once started treatment, CD+4 
T-cell count analysis is recommended at 6-month intervals. 
During antenatal care, HIV positive mothers are counselled on 
health aspects, feeding options for the infant, and are invited 
to join the support groups for HIV positive pregnant and 
breastfeeding women.  
All babies born to HIV positive mothers receive antiretroviral 
prophylaxis for six weeks to prevent vertical transmission. HIV 
positive women are referred from the maternity or postpartum 
visit to the “child-at-risk” clinic for further follow-up for the 
HIV-exposed infant. The child-at-risk clinic offers services for 
any child that is considered to be at higher risk for different 
health problems, including exposure to HIV3. HIV-exposed 
children at the child-at-risk clinic are monitored on a monthly 
basis. Cotrimoxazole and antiretroviral prophylaxis are 
provided at the clinic. Early infant diagnosis of HIV is offered 
routinely from the age of four weeks onwards. If the test result 
is positive, mother and child are referred to the outpatient 
clinic of the health facility, where the infants’ patient file is 
opened and further care and initiation of ART are given 
following the national guidelines.  If the infant tests HIV 
negative, monthly follow-up visits are recommended at the 
child-at-risk clinic until the age of 18 months, with retesting of 
HIV using rapid tests at 9 months and 18 months, when final 
                                                          
3 Children eligible for the child-at-risk clinic: Low birth weight, twins, infant with absent mother, 
malnutrition, contact with pulmonary tuberculosis, cessation of breastfeeding or exclusive artificial 
feeding less than 12 months, pregnant mother with child less than 18 months, child with 3 in-patient 
period within the last 12 months, post-measles period or other severe disease, child with delay in 
psychomotor development, HIV positive or HIV-exposed infant, infant victim of severe social problems.  
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diagnosis is done. The same algorithm for the rapid tests is 
used as for adults. 
Coverage of initiation antiretroviral drug for PMTCT reached 
96% at the end of 2014 (Figure 6). However, retention to 
PMTCT services is still a challenge in Mozambique. With the 
current PMTCT strategy (Option B+), there is a six-month 
retention of 53% (MOH Program Data, 2014). Only 60% of the 
women registered their child at the child-at-risk clinic in 2014 
(MOH national PMTCT meeting, February 2015). Up to March 
2012, only 44% of the HIV-exposed infants had their dried 
blood spot (DBS) sample drawn for diagnosis of HIV [83]. In 
2010, 19% of the children of HIV positive pregnant women had 
a final HIV test at 18 months [83]. More recently, the vertical 
transmission rate by Early Infant Diagnosis (HIV DNA-PCR 
analysis) in infants 0-2 months was estimated 5.5% in 2013; the 
total vertical transmission by DNA-PCR analysis was 11% at all 
ages (MOH, EID report 2014).  The modelled transmission rate 
at 18 months is estimated at 19.3% [83]. 
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Figure 6. Coverage PMTCT antiretroviral drugs, Mozambique (2002-2014)  
(Source: MOH, national PMTCT meeting, February 2015) 
 
Given the gaps in knowledge of factors influencing the 
MCH/PMTCT program, and the magnitude of the problem in 
Africa and Mozambique, the focus of the  research aims to 
respond questions around the different processes within the 
PMTCT program: HIV incidence, access and retention to HIV 
prevention and HIV care services for mother and their HIV-
exposed and HIV-infected infants. 
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CHAPTER 2: OBJECTIVES 
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2.1.     Justification 
 
Mozambique, with a high prevalence of HIV (15.8% among 
pregnant women [85,86]), has a national PMTCT program with 
a rapid expansion of coverage of services to all district level 
since 2004, but there are still many challenges in achieving 
elimination of paediatric HIV.  
Following the latest Global AIDS Response Progress Report of 
Mozambique, challenges for success of the PTMCT program 
for HIV positive women include [83]:  
 Insufficient access to ART by eligible pregnant women 
under ANC;  
 Low coverage of the PMTCT services;  
 Poor inclusion of the family, male partners and other 
people with decision-making power in the family.  
 
On the other hand, there were no data on incidence of HIV-
infection during pregnancy and postpartum period in 
Mozambique at the time of initiation of this work, being 
important to feed primary prevention strategies and the 
comprehensive PMTCT approach. 
 
To understand more the factors influencing the PMTCT 
program and identifying new strategies, we studied processes 
of the program throughout pregnancy and the postpartum 
period in Mozambique. For the purpose of this thesis, we 
defined the postpartum period as any time between delivery 
and 18 months postpartum. The findings of the research will 
give recommendations to reinforce the national program and 
refine its strategies in the fight against paediatric HIV.  
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2.2.      Objectives 
 
The general objective of this research project is to determine 
the factors that influence the outcomes of the HIV prevention 
of mother-to-child transmission program in Mozambique.  
Objective 1: To evaluate factors influencing mother-to-
child transmission of HIV among pregnant women. 
1. To describe the incidence of HIV among pregnant women 
and its associated risk factors, in a high HIV prevalence 
region in Southern Mozambique (Article 1) 
2. To explore factors influencing testing for HIV among 
partners of women seeking mother and child health 
services in Southern Mozambique (Article 1) 
3. To determine the effect of the use of point-of-care testing 
for CD4+ T-cell count enumeration for HIV positive 
pregnant women on uptake of testing and initiation of 
antiretroviral treatment, and explore the acceptability by 
health care workers in Southern Mozambique  (Article 2) 
 
Objective 2: To evaluate factors influencing mother-to-
child transmission of HIV among postpartum women. 
1. To describe HIV incidence and its associated risk factors 
among postpartum women, and the postpartum HIV 
transmission rate from mother to child in women with 
recent HIV infection during breastfeeding, in a high HIV 
prevalence region in Southern Mozambique (Article 3) 
2. To identify influencing factors on retention in the 
postpartum PMTCT and HIV services for HIV-exposed and 
HIV-infected infants in Mozambique (Article 4).  
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CHAPTER 3:  METHODS AND 
PROCEDURES 
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3.1. Study sites 
 
Study country 
Mozambique, a resource-limited country, is located on the east 
coast of sub-Saharan Africa, neighbouring South-Africa, 
Zimbabwe, Zambia, Malawi and Tanzania. The country is 
divided into three regions (North, Centre and South) with a 
total of 11 provinces. It has a surface of 799,380 km2 and a 
coastline of 2,470km. 
The last census data (2007) show that Mozambique has a 
population of about 21 million inhabitants, with 70% living in 
rural areas. Fifty two percent of the population is female. The 
Northern region has a lower population density (20.5 
habitants/km2) while the Southern region is the most densely 
populated region with 27.7 habitants/km2. The distribution of 
the population per province with stratification per sex is shown 
in table 7 [91]. 
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Table 7. Population of Mozambique, per province and per sex (2007) 
Region Province Population (thousands) Density 
(hab/km2) 
Northern 
Region 
 Total Male Female  
Niassa 1213.4 596.2 617.2 9.4 
Cabo Delgado 1634.2 791.1 843 19.8 
Nampula 4084.7 2015.8 2068.9 50.1 
Central 
Region 
Zambezia 3890.5 1878.2 2012.3 37.0 
Tete 1807.5 879.7 927.8 17.9 
Manica 1438.4 690.1 748.3 23.3 
Sofala 1685.7 820.6 865.1 24.8 
Southern 
Region 
Inhambane 1304.8 580.2 724.7 19.0 
Gaza 1236.3 552.2 684.0 16.3 
Maputo Province 1225.5 585.3 640.2 47.0 
Maputo City 1111.6 540.8 570.8 3705.5 
National  20632.4 9930.2 10702.2 25.8 
 
The national fecundity is estimated at 5.9 (Figure 9, [87]). The 
maternal mortality ratio is estimated at 408/100.000 live births, 
while the infant mortality rate is estimated at 64/1000 live 
births. Contraceptive use is a mere 12.3% and about 53% of the 
births happen less than three years after an earlier pregnancy. 
Women have an average age of 19.4 years at the time of the 
birth of their first child [87]. Only  43% of the women give 
exclusive breastfeeding to their infant under six months of age 
in 2011 [87]. 
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Figure 7. Fecundity in Mozambique, per province (2011) 
 
Study provinces 
The studies for this thesis were done in three provinces and the 
capital city of Maputo, with the main research implemented in 
Gaza and Maputo, both located in the Southern region of 
Mozambique. Figure 7 shows the map of Mozambique with its 
11 provinces, indicating the different study locations.  
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Figure 8. Map of Mozambique and study provinces  
 
HIV prevalence in the adult population (15-49 years) is 19.8% 
in Maputo province and 25.1% in Gaza. Compared to the 
national prevalence of 11.5% among the adult population, 
Southern Mozambique is highly affected by the epidemic 
(Figure 9) [84]. 
Articles 1,2,3,4 
Articles 1,2,3 
Article 4 
Article 4 
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Figure 9. HIV prevalence in Mozambique, per province (2009)  
The qualitative studies included the City of Maputo and Cabo 
Delgado province to reflect the different religious and socio-
cultural contexts. Religion is different for the studied 
provinces: the Northern Region has a mainly Muslim religion 
while the population in Central and Southern Mozambique is 
mainly Christian. Polygamy is traditionally accepted in Gaza 
and Maputo province. 
 
3.2. Study designs, sampling and procedures 
 
The thesis consists of four studies, where quantitative and 
qualitative methodologies are used, in different study designs:  
 
 Prospective cohort study design (Articles 1 and 3)  
Two prospective cohort studies, one among pregnant women 
and one among postpartum women, were done in six rural 
health facilities of Maputo and Gaza provinces, with the 
objective to estimate HIV incidence and its associated risk 
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factors. The studies were conducted in parallel and 
recruitment was done at the same health facilities. The HF 
(Moamba, Magude, Marracuene in Maputo province; Chibuto, 
Chicumbane and Malehice in Gaza province) were selected 
based on the high volume of pregnant women seeking MCH 
services and a high prevalence of HIV. Pregnant women were 
eligible if they were 18 years or older, had a negative HIV rapid 
test (performed per national guidelines), were of gestational 
age 32 weeks or less, and were able to provide informed 
consent. Postpartum women were eligible for participation in 
the study if they were 18 years or older, had an HIV negative 
rapid test (performed per national guidelines), were 0-2 
months postpartum, and were able to provide informed 
consent. A total of 1230 pregnant women and 1221 postpartum 
women were enrolled. 
Pregnant women had a scheduled study visit at enrolment, 28 
weeks of gestational age and delivery. For the postpartum 
cohort, a quarterly visit was scheduled until 18 months 
postpartum (enrolment, 3-6-9-12-15-18 months).  
At each visit, counselling and testing of HIV (rapid test) were 
done and a dried blood sample was stored for later 
confirmation of incident cases through HIV DNA-PCR 
analysis. A structured questionnaire was performed at every 
study visit, covering the following areas: socio-demographic 
characteristics, knowledge of HIV and PMTCT and sexual risk 
behaviour factors. Data collection occurred between April 
2008 and July 2011. All participants provided written consent 
before enrolment.   
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 Quasi-experimental pre-post study design (Article 2) 
A quasi-experimental pre-post study was conducted in four 
rural public health facilities in the provinces of Maputo 
(Moamba, Magude, Marracuene) and Gaza (Macia) to evaluate 
the effect of point-of-care (POC) technologies for haemoglobin 
count, syphilis diagnosis and CD+4 T-cell count analysis, 
performed by MCH nurses at the MCH clinic on uptake of 
testing and to assess acceptability by health care workers. The 
study sites (Moamba, Macia, Magude and Marracuene) were 
selected because of high volume of pregnant women seeking 
MCH services and a high prevalence of HIV. Routine data were 
extracted from existing clinical charts and registers of pregnant 
women who attended first antenatal care visit before and after 
introduction of the POC technologies for haemoglobin and 
syphilis screening, and CD4+ T-cell enumeration.  The survey 
on the acceptability of the use of POC technologies was done 
among health care professionals, before and after the 
introduction. A total of 1673 patient files were reviewed (865 
before and 808 after introduction of POC technologies). For 
the survey, all available MCH and laboratory staff were invited 
to participate, resulting in 22 interviews before and 19 after 
introduction. Data collection was done between November 
2011 and July 2012. A waiver of informed consent was obtained 
for the chart review, while written informed consent was 
provided by the survey participants. 
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 Cross-sectional study design (Articles 1 and 4) 
Two studies were done using a qualitative research 
methodology:  
1. A qualitative study to describe factors influencing male 
partner testing for HIV in four districts in Maputo and 
Gaza province (Article 1). 
The study was conducted in four health facilities and 
surrounding catchment areas in Maputo (Boane, Moamba) 
and Gaza (Chicumbane, Chibuto) province. It included 37 
individual interviews (II) and 11 focus group discussions (FGD) 
with fathers, paternal grandmothers with a grandchild less 
than 2 years of age, pregnant or postpartum women (0-2 years 
postpartum) and MCH nurses. All had a minimum age of 18 
years. Paternal grandmothers were included for their 
influential role in health decisions in the studied region. The 
interviews were done with women attending the MCH clinic, 
fathers attending the outpatient clinic and MCH nurses in the 
four study health facilities. For the health care worker 
interviews, MCH nurses who were available on the day of data 
collection were invited by study staff to participate. The FGD 
were conducted with grandmothers, men, and women living in 
the surrounding communities of the health facilities. The study 
team approached community based organizations or 
community leaders in these areas and informed them of the 
study, who then identified possible participants. Investigators 
used structured interview and FGD guides consisting of 
questions on knowledge, perceptions, attitudes and behaviour 
regarding HIV testing for partners of pregnant women, either 
within MCH services or other services at the health facility. 
Hypothetical scenarios were used as vignettes during the FGD. 
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All participants signed written informed consent before data 
collection. The sample size was based on theoretical 
saturation, where 37 interviews were done (15 men, 10 women, 
12 nurses) and 11 focus group discussions (three with men 
(n=22), four with women (n=35) and four with grandmothers 
(n=36)). Data collection was done in September-October 2011 
by trained study staff 
2. A qualitative study to evaluate motivators and barriers 
of access to HIV care for HIV-exposed and HIV-infected 
infants, in two provinces of Mozambique (Maputo and 
Cabo Delgado) and capital city Maputo (Article 4).  
This study was done in five health facilities and surrounding 
catchment areas in Cabo Delgado province (Macomia, 
Montepuez), Maputo province (Marracuene, Magude) and the 
city of Maputo. A total of 79 individual interviews with 
parents/caregivers, health care workers (HCW), and 
community leaders; 32 FGD with parents/caregivers who 
attended and who defaulted from MCH services, maternal and 
paternal grandmothers, and community leaders were done. 
Grandmothers were included because of their influential role 
in families within the Mozambican context. Community 
leaders play an important influential role in the communities 
and were therefore also included.  
Caregivers in study facilities were identified by HCW. Those 
willing to consider study participation were referred to trained 
study staff members.  Caregivers who defaulted were identified 
by HCW through the existing active tracing systems utilized by 
the health facilities in the catchment area. Interested 
caregivers were referred to study staff, who screened them for 
eligibility and conducted interviews after obtaining informed 
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consent, either at the time of the initial introduction to the 
study or at another time and place, depending on the 
caregivers’ preference.  With support of the administrative 
authorities in facility catchment areas, the study team 
identified and recruited community leaders. Community 
leaders identified grandmothers in the communities 
surrounding study facilities and invited them to a location 
where study staff was present to conduct a FGD. HCW were 
identified by facility administrators. Once referred to the study 
team, all potential participants received further information 
about the study and if interested, underwent the informed 
consent process. Only individuals who were 18 years of age or 
older and provided written informed consent were included in 
the study. 
Guides contained questions on demographics and open-ended 
questions on knowledge, attitudes, behaviour, and perceptions 
contributing to access to care for HIV-exposed and HIV-
infected children. FGD were guided by vignettes depicting 
hypothetical scenarios experienced by caregivers of HIV-
exposed and HIV-infected infants. A conceptual framework 
was adapted from the socioecological framework [92] 
organizing the results in five levels: individual, interpersonal, 
institutional, community and policy. The sample size was 
based on theoretical saturation in each of the districts, where 
79 interviews were done (43 caregivers, 16 health care workers, 
20 community leaders) and 31 focus group discussions (eight 
with caregivers (n=48), five with health care workers (lay 
counsellors) (n=28), 10 with community leaders (n=76) and 
eight with grandmothers (n=59). Data were collected between 
August 2011 and January 2012 by trained study staff. 
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3.3. Data management and analysis  
 
 Cohort studies  
 
Data from the questionnaires and laboratory results were 
entered in the software EpiData Version 1.1. Double entry was 
done for all data. Statistical analyses were generated using 
SAS/STAT software, Version 9.2 of the SAS System for 
Windows (SAS Institute Inc., Cary, NC, USA). Seroincidence 
rates were calculated using the number of new HIV infections 
per 100 women-years at risk, based on women’s exposure time. 
Exposure time was calculated as the interval between time of 
enrolment until the last negative HIV test for non-
seroconverters and until the time of HIV infection for 
seroconverters, which was estimated as the midpoint between 
the last negative HIV rapid test result and the first positive HIV 
rapid test result. Seroincidence rates were compared with 
women’s baseline socio-demographic characteristics, 
knowledge on HIV/PMTCT and sexual behaviours employing 
bivariable Poisson regression models. Significance levels were 
set at p≤0.05. The HIV vertical transmission rate among newly 
diagnosed women was calculated as the proportion of HIV-
infected infants over the total number of infants with an initial 
HIV test after detection of maternal seroconversion. 
Descriptive analysis was done using univariate analysis.  
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 Quasi-experimental study  
Routine data were extracted from existing patient records and 
registers were transferred onto specific data extraction forms 
and entered into a database. Data were analysed using STATA 
Version SE/11.1 (Stata Corp, Texas, US). We compared study 
outcomes before and after introduction of the POC 
technologies, using the z-test (categorical variables) and 
Wilcoxon rank-sum test (continuous variables). In the pooled 
analysis, proportions before and after were estimated using 
inverse variance weights to adjust for possible cluster effects. 
Survey data were compared using the Fisher’s Exact test. 
 
 Qualitative studies 
The qualitative studies included key informant interviews 
and/or focus group discussions. Audio recordings and notes 
from all the FGD and II were translated into Portuguese and 
transcribed into Microsoft Word. The transcripts were 
manually coded for content by two researchers working 
independently. Codes were developed inductively and the 
main themes were identified. The results of the two 
researchers were compared to assess inter-rater reliability; 
consensus was reached in areas of disagreement. For both 
articles 1 and 4, MAXqda Version 10 (Verbi GmbH, Berlin, 
Germany) was used for analysis of the qualitative data. 
Participant demographic data were analysed using the 
statistical software package Stata Version 11.0/SE (StataCorp, 
Texas, USA) and were described.  
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3.4. Ethical approvals 
 
All study protocols in the thesis were approved by the National 
Committee of Health Ethics, Ministry of Health (“CNBS – 
Comité Nacional de Bioética em Saúde”). The protocols that 
resulted in articles 2 and 4 were additionally approved by The 
George Washington University Institutional Review Board.  
All studies got administrative approval of the Ministry of 
Health, Mozambique.  For the cohort study, the qualitative 
studies and acceptability survey, written informed consent was 
obtained from all participants. A waiver of informed consent 
was provided for the retrospective chart review.  
All data from the studies were stored in databases that were 
protected and accessed only by the study investigators.  
 
3.5. Dissemination of results  
 
The thesis is based on following papers, published in 
international peer-reviewed journals: 
Article 1:  
De Schacht C, Hoffman HJ, Mabunda N, Lucas C, Alons CL, 
Madonela A, Vubil A, Ferreira OC Jr, Calú N, Santos IS, Jani IV, 
Guay L. High rates of HIV seroconversion in pregnant women 
and low reported levels of HIV testing among male partners in 
Southern Mozambique: results from a mixed methods study.  
PlosOne 2014, 9(12): e115014 
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Article 2:  
De Schacht C, Lucas C, Sitoe N, Machekano R, Chongo P, 
Temmerman M, Tobaiwa O, Guay L, Kassaye S, Jani I. 
Implementation of point-of-care diagnostics leads to variable 
uptake of syphilis, anemia and CD4 testing in rural maternal 
and child health clinics in Mozambique.  
PLoS One 2015, 10(8): e0135744  
 
Article 3:  
De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calú N, 
Santos I, Hoffman HJ, Alons C, Guay L, Jani IV. High HIV 
incidence in the postpartum period sustains vertical 
transmission in settings with generalized epidemics: a cohort 
study in Southern Mozambique.  
Journal of the International AIDS Society 2014, 17:18808 
 
Article 4: De Schacht C, Lucas C, Mboa C, Gill M, Macasse E, 
Stélio AD, Bobrow EA, Guay L. Access to HIV prevention and 
care for HIV-exposed and HIV-infected infants: a qualitative 
study in rural and urban Mozambique.  
BMC Public Health 2014, 14:1240 
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The results section is divided into two components:  study 
results of the assessment of factors influencing PMTCT 
program outcomes during pregnancy and results of research 
looking at factors during the postpartum period. 
 
4.1.     Pregnancy  
Article 1 - High rates of HIV seroconversion in pregnant 
women and low reported levels of HIV testing among 
male partners in Southern Mozambique: results from a 
mixed methods study  
 
 
De Schacht C, Hoffman HJ, Mabunda N, Lucas C, Alons CL, 
Madonela A, Vubil A, Ferreira OC Jr, Calú N, Santos IS, Jani 
IV, Guay L.  
 
 
PlosOne 2014, 9(12): e115014  
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Article 2 - Implementation of point-of-care diagnostics 
leads to variable uptake of syphilis, anemia and CD4 
testing in rural maternal and child health clinics in 
Mozambique  
 
De Schacht C, Lucas C, Sitoe N, Machekano R, Chongo P, 
Temmerman M, Tobaiwa O, Guay L, Kassaye S, Jani I. 
PLoS One. 2015, 10(8):e0135744 
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4.2.     Postpartum period  
 
Article 3 - High HIV incidence in the postpartum period 
sustains vertical transmission in settings with 
generalized epidemics: a cohort study in Southern 
Mozambique 
 
 
De Schacht C, Mabunda N, Ferreira OC, Ismael N, Calú N, 
Santos I, Hoffman HJ, Alons C, Guay L, Jani IV. 
 
 
Journal of the International AIDS Society 2014, 17:18808 
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Article 4 - Access to HIV prevention and care for HIV-
exposed and HIV-infected infants: a qualitative study in 
rural and urban Mozambique 
 
De Schacht C, Lucas C, Mboa C, Gill M, Macasse E, Stélio AD, 
Bobrow EA, Guay L.  
BMC Public Health 2014, 14:1240 
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CHAPTER 5:  DISCUSSION 
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5.1. Key findings 
 
The thesis consists of evaluations of factors influencing 
outcomes of HIV prevention of mother-to-child transmission 
programs during the prenatal (Articles 1 and 2) and postpartum 
period (Articles 3 and 4). Many of the identified factors 
influencing PMTCT programs are weaved throughout 
pregnancy and the postpartum period. 
The results of the studies show that lost opportunities to 
prevent mother-to-child transmission continue to exist, 
despite the progress of the country’s program of fight against 
paediatric HIV.  Our research has shown that 1) the incidence 
of HIV among pregnant and breastfeeding women was high – 
especially in young women –and is resulting in an increased 
vertical transmission rate; 2) access to care for HIV-positive 
pregnant women did not increase using point-of-care 
diagnostic technologies and was influenced by contextual 
factors; 3) barriers to access and retention of HIV prevention 
care for HIV-exposed infants and HIV care for HIV-infected 
infants are mostly individual level and need specific strategies 
involving community; and 4) knowledge of partner testing of 
HIV is low and requiring men-targeted strategies to increase 
couple-knowledge of HIV status.  
Primary prevention is the first prong of PMTCT strategy. In two 
studies (Article 1 and 3), we evaluated the risk of new infection 
during pregnancy and breastfeeding period, to understand the 
epidemic better in this population. Incidence of HIV is high 
both during pregnancy and postpartum period (3.2 and 4.3 per 
100 women years, respectively) (Articles 1 and 3). Among 
postpartum women, incidence was significantly higher in 
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younger population (RR 0.93 (0.87-0.99); p=0.02). Risk factors 
for acquiring HIV during pregnancy are early sexual debut and 
living in Maputo province. During the postpartum period, 
young age, having a low number of children, higher education 
of woman´s partner and having sex with someone other than 
one’s partner were identified as risk factors.  We saw that the 
vertical transmission due to maternal acute infection of HIV 
during the postpartum period is estimated at 16% in our 
cohort. 
To evaluate access to care and treatment for HIV-positive 
pregnant women – related to prong 3 of the PMTCT strategy – 
we studied the use of point-of-care testing for CD4+ T-cell 
counting performed at MCH services. At the time of the 
research, Option A was the recommended regimen for PMTCT 
in Mozambique, where CD4+ T-cell count analysis was 
required for determination of eligibility and initiation of 
antiretroviral treatment. We found that the coverage of testing 
did not differ significantly, but time from HIV diagnosis to 
treatment decreased. However, variability in coverage of 
testing uptake was high between the four health facilities, 
suggesting other contextual factors playing a role (Article 2).   
In order to close the cascade of PMTCT, follow-up of the HIV-
exposed infants until final diagnosis and care for the HIV-
infected infants are crucial. Retention in HIV services for HIV-
exposed and HIV-infected children is known to be low. The 
qualitative study described in article 4 explored influencing 
factors, which were described in five levels of influence 
(individual, interpersonal, institutional, community and 
policy). Barriers are mainly individual-level barriers where 
stigma, preference of alternative care (outside the 
conventional health facilities) and disbelief in results are still 
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important. What facilitates retention in services is having hope 
for the future of the child, presence of symptomatic illness and 
the belief that the health facility is the appropriate place for 
care. Recommendations given by the participants included 
more information and awareness in the community about HIV 
and preventive care for HIV-exposed children, improvement of 
patient flow and organizing outreach activities in the 
community.  
Since couple knowledge of HIV-status is important as a 
primary prevention strategy, we looked at male HIV testing 
uptake. We found that while HIV-testing coverage at antenatal 
care is high, knowledge of male HIV testing is low. Our results 
show that only 19% of partners are reported by their spouse to 
have been tested f0r HIV, while 56% of women reported that 
their partner was not tested (Article 1). Using qualitative 
methods, interviewing men, women and health care 
professionals, showed that fear of stigma and discrimination, 
but also the preconception that clinics are places for women, 
are important factors that hinder uptake of male partner HIV 
testing. What motivates men to go for HIV testing is the 
knowledge that it is necessary as one can’t assume the result to 
be the same as that from partner or child. A (formal) invitation 
given by HCW would increase acceptance of HIV testing.  
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5.2. Discussion 
 
1. New HIV infection during the antenatal and postnatal 
periods and associated risk factors  
 
Primary prevention of HIV is a challenge for any population, as 
behavioural changes are difficult and influenced by cultural 
and social context. The findings from the studies presented in 
articles 1 and 3 show a high incidence of HIV among pregnant 
and postpartum women (4.3 and 3.2 per 100 women years, 
respectively). Other studies done in sub-Saharan Africa show 
results with rates ranging between 0 and 8 per 100 women 
years, with the exception of Swaziland and the neighbouring 
Kwazulu Natal region in South-Africa, where estimations are 
much higher (16.8/100 women years in Swaziland [93]; 10.7/100 
women years in South-Africa [32]) [94]. No significant 
differences in incidence were seen among pregnant and 
postpartum women. Female non-pregnant “higher-risk” 
populations in Mozambique have an incidence of 4.6 and 6.5 
per 100 women years [95,96]. Comparing to a high-risk 
population of female sex workers in sub-Saharan Africa, where 
incidence rates are of HIV seen between 2.7 and 5.6 per 100 
women years [97,98], pregnant and postpartum women in an 
endemic region of HIV should be considered as a 
subpopulation at higher risk and therefore, in need of special 
attention to primary prevention.  
 
Studies in this thesis found high incidence rates among young 
women (4.9 per 100 women years in the age group of 18-19 
years, postpartum (Article 3)). This is an alarming finding, 
showing the need for a multi-sectoral approach, where the 
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Ministries of Health, Education, and Youth should be main 
players in developing and monitoring targeted HIV prevention 
strategies. These should be comprehensive and integrated in 
health prevention programs, including healthy lifestyle, 
prevention of sexually transmitted diseases and family 
planning. The Ministry of Health’s national health system 
includes a clinic for adolescents and youth (“SAAJ” or “Serviços 
Amigos de Adolescentes e Jovens” – “Services Friends of 
Adolescents and Youth”). Services on reproductive health, 
nutrition, hygiene and mental health are offered to youths, 
according the “SAAJ” national guidelines. In many rural health 
settings, the services are currently underutilized but could be 
an entry point to reach young girls.  
 
Mozambique’s HIV prevalence rates among young people are 
also high, with a female-male disparity [84]. The highest rates 
among women were seen in the age group 25-29 years (16.8%) 
and in men between 35-39 years (14.2%). The median age of 
sexual debut in women and men aged 20-49 years is 16.5 and 
17.7, respectively [84]. In the young age group of 15-19 years, 
HIV prevalence among girls is as high as 7.1%, while for boys it 
is 2.7%. Once more, the need for more education on sexually 
transmitted diseases and sexual behaviour with prevention 
strategies is clear. This should go beyond schools, as about 36% 
of girls and 21.2% for boys 15-17 years old are not attending 
school in Mozambique [84]. Community outreaches and 
working with community and church leaders, or other 
influencing people in the community, will be crucial to reach 
this vulnerable population.  
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The same national survey on HIV done in 2009 showed that 
only 32% of women and 35% of men aged 15-49 years had a 
comprehensive knowledge about HIV4 [84]. Knowledge of 
modes of vertical transmission is higher among women than 
men (Figure 9 [84,87]). Our study also showed a high 
knowledge level on PMTCT risk among women, but there is a 
possible bias as the study participants attend MCH care where 
counselling on MCH and PMTCT is regularly given. Knowledge 
(or absence of) was not seen as a risk factor for primary HIV 
infection in our studies (Articles 1 and 3).  
 
 
Figure 10. Knowledge of PMTCT among women and men aged 15-49 years, 
Mozambique (2003-2009).  
HDS – Health Demographic Survey; INSIDA – “Inquérito nacional de prevalência, riscos 
comportamentais e informação sobre HIV/SIDA em Moçambique” 
 
                                                          
4 Comprehensive knowledge in the survey is defined as “knowing that consistent use of condom during 
sexual relationships, having only one sexual partner not infected and being faithful, can reduce risk of HIV 
infection; knowing that a person that appears healthy can have HIV; and to recognize the two most 
common wrong ideas on HIV transmission and prevention (transmission of HIV via mosquito bite and 
transmission of HIV through supernatural forces).  
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Knowing one’s status is the first step in HIV prevention. In the 
studies on HIV incidence (Articles 1 and 3), just about half of 
the pregnant women reported to ever have been tested before 
their current pregnancy, but more than 90% of the postpartum 
women said they were tested before enrolment, reflecting the 
success of opt-out HIV testing at antenatal care. The national 
policy on HIV testing during pregnancy includes opt-out 
testing at 1st ANC visit. Coverage of HIV testing at first 
antenatal care is 90% in Mozambique (MOH, 2014). Regular 
retesting for HIV is recommended to identify maternal HIV 
infection as soon as possible. The national policy in 
Mozambique includes provider initiated HIV counselling and 
testing at each entry point of the health facility when eligible 
(defined as not been tested for HIV during the last three 
months), giving the opportunity for retesting throughout all 
postpartum MCH service delivery points. However, no routine 
data are currently available on re-testing throughout MCH, but 
is an important tool to monitoring the epidemic and estimate 
impact on vertical transmission. 
 
2. Vertical transmission as a result of acute maternal HIV 
infection 
 
In the study described in article 3, 21% of the infants of the 
women with a postpartum acute HIV infection acquired HIV. 
This number, however, needs to be interpreted with caution, 
as only a small number of infants were tested, giving a wide 
confidence interval.  In an extrapolated calculation, about one 
of eight infants are infected due to an incidental maternal HIV 
infection during breastfeeding. A recent study done in South-
Africa showed that acute maternal infection during pregnancy 
 128 
 
accounted for 26% of the early vertical transmission of HIV 
[99]. Early maternal HIV diagnosis can lead to immediate 
treatment of the mother to protect the infant. Regular HIV 
testing of mothers after delivery (and fathers, if going to care 
with their child), at every of the (monthly or bimonthly) well-
child visits, and at every clinic visit outside of these scheduled 
visits, can lead to early detection of maternal HIV infection. 
This strategy to identify and follow HIV-exposed infants and 
their mothers has been shown to be acceptable [100], so could 
be extended for re-testing of mothers attending well-child visit 
for their infant. However, in many African countries, not only 
mothers bring the infants to vaccination visits, so we still might 
miss some of the mothers with an incident HIV infection.  
The median period of breastfeeding in Mozambique is 20.8 
months, while women give exclusive breastfeeding for a 
median time of 1.3 months [87]. In our study described in 
article 3, 63% were still breastfeeding at 18 months. We found 
that about two thirds of the mothers acquired HIV after the six 
first months of life of the infant (Article 3), again showing the 
importance of early detection as the risk of transmission in 
acute infections is high as most women are still breastfeeding.   
 
3. Access to and retention in PMTCT services  
 
Significant efforts are made on secondary prevention of 
mother-to-child transmission of HIV, with progresses on 
antiretroviral prophylaxis and treatment strategies in the last 
decade. As of July 2013, the Mozambican national program of 
prophylaxis and treatment for HIV positive women offers 
lifelong antiretroviral treatment for all HIV positive pregnant 
and breastfeeding women regardless of their immunological or 
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clinical status (Option B+). With this current policy, analysis 
of the CD4+ T-cell count is therefore not required for defining 
eligibility, but is still necessary for monitoring of treatment 
since HIV viral load testing is still largely unavailable. For 
maternal incident HIV infection, an immediate initiation of 
maternal ART after a postpartum HIV diagnosis might still be 
too late to prevent vertical transmission, due to the time it 
takes to decrease the high viral load, present during acute 
infection. Immediate infant prophylaxis with nevirapine 
(recommended by WHO until six weeks after maternal ART 
initiation [49]) is therefore critical to decrease further risk of 
transmission.  
At the time of the study described in article 2, the CD4+ T-cell 
count analysis was still crucial to evaluate eligibility of HIV 
positive pregnant women for antiretroviral treatment. 
Bringing this and other tests closer to patients could 
potentially increase uptake of diagnostic tests and possibly 
ensure therapeutic interventions. This was seen in an HIV 
positive adult population, when POC technologies were 
brought to the health facilities’ laboratories [78]. However, in 
the study described in article 2, bringing the test down to the 
MCH clinic did not increase uptake of testing for CD4+ T-cell 
enumeration. Nevertheless, and importantly, the introduction 
of POC technologies decreased the time from HIV diagnosis to 
CD4+ T-cell counting and to treatment initiation. Our findings 
confirm the statement that contextual factors play a role on 
coverage of testing and initiation of treatment [101]. 
Interestingly, making POC technologies available at the MCH 
clinic was well accepted by the MCH nurses, but the perception 
of the positive impact on the number of women initiating 
antiretroviral treatment was less optimistic after the 
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introduction of POC technologies. This is an important finding 
as the uptake of ART among HIV positive eligible women is a 
complex issue, with access to diagnostics playing an important 
but non-exclusive role.  
The study described in article 2 also investigated the effect of 
introducing POC technologies for anaemia and syphilis testing 
at antenatal care as well as the effect of offering a package of 
three screening tests (haemoglobin, syphilis and CD4+ T-cell 
count) to HIV positive women. Variable results were seen 
between the different health facilities in the uptake of the 
screening tests. This confirms again the importance of 
contextual factors, influencing not only HIV services, but MCH 
services in general. While the introduction of new technologies 
constitutes an opportunity for improving access and efficiency 
of health services, it is increasingly evident that success is 
largely variable and that implementation science should play a 
critical role in guiding the deployment of technologies. 
 
Retention of mother and infants in HIV services remains a 
critical challenge. A review by Sibanda shows a loss of 49% 
from first antenatal care to delivery, 34% within the three 
months of delivery and 46% after the first HIV test [73]. The 
recent national PMTCT meeting held in Maputo in February 
2015 showed that only 60% of women registered their infant at 
the child-at-risk clinic. Our study results of the qualitative 
study show that individual-level factors such as stigma and 
preference of seeking health services outside the national 
health services, are the main factors influencing health seeking 
behaviour for PMTCT services (Article 4). The one-stop model 
for ART delivery for mother at postnatal care (where an HIV 
positive mother and her HIV-exposed child are seen in an 
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integrated visit at the child-at-risk clinic) is being 
implemented since 2014 in Mozambique, expecting to increase 
retention for both mother and child. Integration of HIV 
prevention services for mothers and HIV-exposed infants 
within routine immunization was explored [100,102] and could 
contribute to a higher uptake and increase of services for HIV-
exposed infants. However, monitoring of immunization 
coverage should be done, especially in countries with a sub-
optimal vaccination coverage such as Mozambique, where only 
52% of the children are completely vaccinated5 [87].  
 
Retention in MCH care services in general is a known challenge 
and makes the difficulties of retention in the PMTCT program 
not unique nor a surprise. Worldwide, in 2013, 56% of pregnant 
women had their minimum of four antenatal care visits; in low 
income countries this was only 38% [6]. In Mozambique, 51% 
of the pregnant women had their minimum of four visits, 55% 
have an institutional delivery and 52% of the children are 
completely vaccinated [87]. A comprehensive approach, 
focused not only on HIV, but on preventive and curative care 
for women in reproductive age and their infants, could 
potentially increase uptake and adherence to MCH/PMTCT 
services. This, however, could mean a possible re-organization 
of health services, such as primary preventive and curative care 
offered in “family-oriented” clinics rather than in “mother and 
child-oriented” clinics. Other initiatives as mobile 
technologies or community based preventive clinic visits, 
using the routine outreach visits and working with community 
                                                          
5 Completely vaccinated is defined as having completed the eight vaccines (BCG, measles, three doses of 
pentavalent vaccine (DTP+ Hepatitis B + Haemophilus Influenzae type B (HiB)), three doses of polio 
vaccine) at 12 months of age 
 132 
 
health workers, could contribute to higher uptake and 
retention. 
 
4. Community involvement and education 
Barriers to access to ANC services have been described on 
individual, social or community level, such as social and 
cultural context or interactions with health care workers [103-
105]. A review of barriers to access to MCH and PMTCT services 
showed that additional barriers were present: social norms, 
knowledge and socioeconomic status are the predominant 
factors, where transport, non-disclosure, stigma and partner 
relationships are most frequently mentioned [106].  The studies 
described in articles 1 and 4 show that stigma and fear of 
discrimination are seen as barriers to uptake of male partner 
HIV-testing and to retention in postpartum PMTCT services, 
putting the need to reinforce or introduce stigma reduction 
strategies as a priority. Stigma has also been seen as a major 
barrier to access and adhere to the different steps of the 
PMTCT cascade [107], and to adherence to exclusive 
breastfeeding [108]. Women of reproductive age, pregnant and 
postnatal women need a specific attention, but family and 
community decision makers should be included in the 
definition and/or implementation of the strategies.  
The same studies (Articles 1 and 4) also show that community 
linkage for different aspects of PMTCT services (such as HIV 
testing for male partners, follow-up for HIV-exposed and HIV-
infected infants, retesting for HIV of breastfeeding women, 
importance of exclusive breastfeeding in the first six months) 
is still weak. These linkages are crucial to increase access and 
retention to health services, and to disseminate information 
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and mobilization on HIV, PMTCT and services. While 
strengthening the outreach activities to the community are 
important, efforts should be made on the information 
messages. Information and awareness, focusing on changing 
the individual-level beliefs, on the benefits of early paediatric 
testing and treatment, including positive messages of hope 
and/or success stories and the meaning of chronic disease care 
is necessary. The communication strategies should also be 
targeted to influential family members such as grandmothers 
and fathers, community leaders, or other community and 
family decision makers. 
Education of the community and of health care workers is an 
important step. Health care messages towards community 
members are given through different ways. Radio messages are 
very often used, as this remains the most used social media in 
rural areas in Mozambique. Community health workers 
(CHW) have their role in dissemination of health messages, in 
which PMTCT messages are included. However, many vertical 
programs count on the support of the CHW. The terms of 
references of the CHW are currently being revised by the 
Ministry of Health, aiming at a better coordination of the 
activities. A recent review shows a growing importance of 
community health workers, who can increase access to care, 
and improve linkages with communities [109]. Besides this 
important link, Mozambique’s district authorities organize 
community health committees that should bring community 
and health care services closer. It is a forum where health issues 
are discussed and linkages coordinated. However, no 
evaluation has been done on the effect on knowledge transfer 
or health seeking behaviour.  
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5. Male involvement  
 
Male involvement can contribute to improve retention of 
women in MCH/PMTCT care. A study revealed that male 
involvement in PMTCT services was associated with decreased 
risk of infant HIV infection [110]. Male partners are the main 
family decision makers on health issues and health seeking 
behaviour. Before implementation of the opt-out strategy of 
HIV testing at antenatal care services, this was described as a 
barrier for women to get their HIV test [111-113].  
Southern Mozambique is patriarchal, and the influence of the 
male partner and his family (mainly his mother, who has 
decision authority in his absence) on decisions on health 
seeking behaviour is very strong. Strategies for partner testing 
are scarce; invitation is recommended in the Mozambican 
guidelines, but in practice only done verbally. There are no 
good data on uptake of male partner testing or couple testing 
in Mozambique or other African countries. A study in Nairobi 
for example, shows an uptake of couple testing of 16% within 
MCH [114]. Nineteen percent of the pregnant women reported 
that their partner was tested for HIV (Article 1). Couple testing 
and knowledge of each other’s HIV status can lead to couple 
decisions on family planning and primary prevention of HIV 
within the serodiscordant or seroconcordant couple. A 
randomized trial increased couple attendance by 10%, but 
overall uptake remained low (16.2%). But, more than 90% of 
male partners who attended the ANC visit accepted HIV 
testing [115]. The study in the thesis (Article 1) showed that a 
written invitation coming from health care services is more 
appreciated by men than a verbal invitation passed from the 
MCH nurse to the women. Health messages are sent by mobile 
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technologies (SMS) in Mozambique mainly for mother and 
child health issues, but messages inviting men for HIV testing 
may be worth exploring.  
Besides personal barriers such as fear of stigma or 
discrimination, the health facility is often seen by men as being 
a place for women only, where no male-friendly services exist 
(Article 1). Couple testing strategies require a comprehensive 
strategy, with education, mobilization for both men and 
women in the community, and re-structuring of health facility 
flow to accommodate the needs of men.  
An aspect to highlight is that challenges of male involvement 
do not only exist for HIV testing and HIV prophylaxis and care, 
but is a broader issue when talking about mother and child 
health services. Reported reasons for poor male participation 
in antenatal care services were negative attitudes by health 
care workers, pregnancy support seen as a female activity and 
no couple-friendly environments [116,117]. Initiatives to create 
male friendly health clinics, with primary health care 
prevention (hypertension, healthy living, vaccination services 
for men, etc.) should be further explored on its acceptability, 
feasibility and effect on male testing and male involvement. An 
important consideration to be taken is that transport costs 
potentially increase if both partners attend the clinic. Besides 
inviting male partners to the health facility, it may also be 
worthwhile exploring is testing opportunities outside of the 
health facility setting for men, such as community location, 
home testing etc. as it might not be viable to expect that they 
will come to the health facility/MCH clinic for counselling and 
testing. Therefore, a combination of institutional and 
community initiatives should be undertaken.  
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Another major challenge in Southern Mozambique is the fact 
that many male partners work as migrants (most going to 
South-Africa as mine workers). Although results described in 
articles 1 and 3 did not show that having a partner working as 
a migrant worker or being away for more than a month was 
associated with a higher risk for the woman, a review showed 
an association between migrant work and HIV risk among men 
[118]. A recent survey revealed that the HIV prevalence among 
mineworkers who mainly originate from Southern 
Mozambique is 22.3% [119]. Recently, Mozambique and South-
Africa agreed on harmonizing HIV-services in order to improve 
continuous care of the migrant workers. Collaboration with 
mining companies, borders, bus companies organizing 
transport to and from mining locations etc. need to be 
explored.  
 
6. Human resources 
Lack of human resources in specific sectors is an important 
aspect influencing success of services, especially since the 
beginning of the HIV epidemic. A study in Central 
Mozambique showed a higher attrition to ART services in 
health facilities with more pharmacy staff available [120]. In the 
context of PMTCT, HIV care services (including HIV testing for 
all women attending ANC care, antiretroviral treatment and 
prophylaxis delivery for pregnant women, follow-up after 
delivery for mother and HIV-exposed child, HIV-testing of the 
infant (Early Infant Diagnosis) and counselling at all contacts), 
are activities that are added to the routine pre- and postnatal 
care, and all done by MCH nurses. This has a possible negative 
influence on the quality of other MCH services, without a 
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significant change in quantity of nurses. The number of health 
care professionals in Mozambique increased from a total of 
33,122 in 2009 to 41,948 in 2013. From those, the total MCH 
nurses changed from 2,949 (2009) to 3,692 (2013), reflecting a 
ratio of MCH nurses of 15.2 per 100,000 inhabitants in 2013 [121]. 
This increase of is not enough for the 1.4 million women going 
for a first antenatal care visit in 2014, of whom, 125,000 HIV 
positive (MOH, 2014).  
Task shifting of HIV service provision from physicians to non-
physician clinicians was explored, evaluated and adopted in 
Mozambique with the expansion of adult ART services [122-
125]. A fluent patient flow is essential not only for access to 
care, but retention to services. Further task-shifting to lay 
counsellors should be explored more. Point-of-care 
technologies get some laboratory tests closer to or at service 
delivery (“point-of-care”). Therefore, the need of return visits 
for blood collection (in the case of women arriving late at the 
laboratory after their ANC visit and are asked to come back the 
next day) or for receiving laboratory results decreases, and thus 
risk of defaulting. When used at MCH clinics, MCH nurses may 
not in the best position to perform the tests, because they are 
few in number, and overloaded with many activities, including 
HIV care and treatment given at the MCH clinic. The study 
described in article 2 showed that MCH nurses did not increase 
coverage of testing. Task shifting POC technologies to lay 
counsellors could be beneficial, as they can play a role in 
offering health counselling for pregnant women while waiting 
for results.  
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5.3. Limitations 
 
The presented research studies are not without limitations. 
The work is mainly done in Southern Mozambique with 
different epidemiologic characteristics than the Central or 
Northern region and might not be generalizable for 
Mozambique. However, the Southern region has an active HIV 
epidemic with a high burden of disease for the country, making 
the results important to policy decision makers.   
One of the limitations of the cohort study was the high loss to 
follow-up. The study was conducted in an operational research 
setting, within the existing national health system. Although 
the loss to follow-up was high, it was still possible to achieve 
significant results, having the additional advantage of working 
in a “real life” setting of health services. Strict procedures, 
regular supervision and monitoring visits, and continuous on-
the-job training of protocol procedures were put in place to 
maintain quality.  
Social desirability bias is expected in qualitative research. 
Interviewing different target groups, combining interviews and 
focus group discussion where possible, and using probes 
decreased (but does not eliminate) this bias.   
We could not measure the impact of acute maternal infection 
during pregnancy, due to the low number of seroconversions.  
Finally, I did not study family planning issues for HIV positive 
women, as one of the strategies to prevent vertical 
transmission of HIV.  
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CHAPTER 6: RECOMMENDATIONS 
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6.1. Recommendations for policy makers  
 
As a main recommendation for policy makers, young 
adolescent girls, pregnant and breastfeeding women need to 
be recognized as key populations:  
1) Young adolescent girls have specific needs and require 
specific strategies. This means a close collaboration 
between Ministries of Health, Education and Youth, in 
order to reach this specific group. Revisiting the Adolescent 
and Youth clinics with comprehensive approaches, 
including contraception and screening and prevention of 
sexually transmitted infections, is needed to achieve a high 
coverage of service use. 
2) Pregnant and breastfeeding women are in high need of 
targeted HIV prevention services. The results of the studies 
related to this (Articles 1 and 2) have been presented at the 
2012 national scientific conference where HIV incidence in 
different populations in Mozambique was discussed in a 
symposium. This led to some recommendations such as 
community involvement to transmit targeted messages and 
support in referral to health facilities of HIV-positive 
pregnant and breastfeeding women. The results have also 
been discussed in fora where also non-governmental 
organizations and donors participated, and debated what 
can be integrated in their plans that support the MOH’ HIV 
programs. 
Another recommendation is the reinforcement of HIV 
retesting activities during pregnancy and postpartum period. 
The Ministry of Health revised the PMTCT guidelines on HIV 
testing to provider-initiated testing at all entry points. At each 
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clinic visit during pre- and postnatal care, there is opportunity 
for HIV (re)-testing. HIV counselling and testing during 
antenatal care is routinely done at first visit and delivery, but 
efforts should be made for regular retesting during the 
breastfeeding period, for example at each vaccination visit of 
the infant. Adequate monitoring systems need to be put in 
place to ensure this testing is done and to allow for a prompt 
response to newly identified HIV positive women, with 
immediate initiation of antiretroviral therapy.  
Point-of-care testing for CD4+ T-cell count is being 
implemented in many health facilities in Mozambique, but not 
always reaching HIV positive pregnant women as soon as they 
are diagnosed. Introduction of the technologies requires a site 
level discussion and review of processes and flows, as many 
contextual factors influence results of new diagnostic 
technologies, as seen in article 2.  
Retention to HIV-care in general and specific to PMTCT 
services has been a topic discussed at national and 
international level. Study results published in article 4 
recommend targeted and continuous messages on the 
importance of adherence to services, on infant diagnosis and 
treatment including success stories may improve retention. 
During the national PMTCT meeting (February 2015), these 
results have been used in the discussion of a new 
communication strategy and community involvement to 
increase retention. Continued work on socio-cultural changes, 
where cultural habits are respected while changing health 
seeking behaviours. This requires more input from influential 
community members in health promotion. 
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Finally, new innovative patient flow aiming at a better patient 
flow, a better male involvement into the different services, and 
integrating services could increase uptake of services. This 
could imply a revision of the current health system and going 
towards a “family” health clinic instead of “mother and child” 
health clinic. This should include the integration of support 
services such as laboratory, pharmacy and counselling in this 
clinic to avoid dropout. However, this major change in health 
service delivery needs much more discussion with high-level 
policy makers and requires more implementation research to 
show evidence.  
 
6.2.  Recommendations for future research 
 
Operations research testing new strategies to increase access 
to PMTCT services resulting from the qualitative work is 
needed: mobile community visits; male friendly health clinics; 
feasibility of regular re-testing of mothers at the well child 
visits and/or community outreach vaccination visits; 
evaluating effectiveness of health prevention strategies for girls 
within the Adolescent and Youth Clinics. Education strategies 
in the community need to be evaluated on acceptability, 
(sustained) knowledge and eventually behavioural changes. 
mHealth initiative sending information on MCH services, HIV 
testing, couple testing and retention by cell phone messages to 
both women and men may have an effect and need to be 
explored.  
Implementation science on feasibility and effectiveness of 
family clinics in Mozambican urban and rural health facilities 
are needed to evaluate effect on male involvement in health 
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services and particularly PMTCT services, and on retention of 
women in MCH/PMTCT services. 
Combination primary prevention strategies including pre-
exposure prophylaxis and behavioural change intervention in 
vulnerable and at-risk groups should be explored. These 
include pregnant women in high HIV prevalence regions or 
discordant couples. However, for the latter, couple testing is 
required.  
Developing and evaluating monitoring tools, embedded in the 
routine health system, to estimate HIV incidence in this cohort 
is urged to follow the impact on vertical transmission and 
monitor epidemiological trends of the HIV epidemic.  
For HIV positive pregnant and breastfeeding women, 
evaluating effectiveness of implementation strategies of 
PMTCT Option B+ are urgently needed, analysing the best 
ways to increase uptake and adherence to therapy and 
prophylaxis for mother and infant, for both groups of women: 
those with an established HIV infection, and women still HIV 
negative and vulnerable to acquiring HIV during pregnancy or 
breastfeeding period.  
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CHAPTER 7: SUMMATION 
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7.1. Summary 
 
The World Health Organization recommends a 
comprehensive approach of prevention of mother-to-child 
transmission of HIV consisting of four prongs: prevention of 
primary infection among women in reproductive age; 
prevention of unintended pregnancies among women living 
with HIV; care and treatment of HIV positive pregnant women; 
family approach for HIV services.  Mozambique, located in 
sub-Saharan Africa, has a high HIV burden with a national 
prevalence of 15.8% among pregnant women (2011). When the 
prevention of mother-to-child transmission (PMTCT) program 
initiated in 2002, a single dose nevirapine was used as 
prophylactic antiretroviral drug, while the current 
recommended regimen consists of lifelong antiretroviral 
treatment for all HIV positive diagnosed pregnant and 
breastfeeding women (Option B+). 
In the thesis, a combination of quantitative and qualitative 
methodologies were used to evaluate factors influencing 
processes of Mozambique’s PMTCT program both during the 
antenatal care period and the postpartum period. We 
investigated risk factors for HIV acquisition during pregnancy 
and breastfeeding period, and access to HIV prevention and 
care for HIV positive women and their HIV-exposed or 
infected infants.  
As described in articles 1 and 3 of this dissertation, the 
incidence of HIV remains high both during pregnancy and the 
postpartum period (3.2 and 4.3 per 100 women years, 
respectively), with a high burden on vertical transmission: one 
of eight infants infected with HIV is due to a postpartum 
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maternal HIV infection. Risk factors for acquiring HIV during 
the postpartum period are young age, low parity, higher 
education of woman’s partner and having sex with someone 
other than one’s partner; during pregnancy, early sexual debut 
and living in Maputo province were also identified as risk 
factors. Strategies of primary prevention of HIV during 
pregnancy and the postpartum period should be tailored for 
them, with a special attention to young girls and women. A 
multi-sectoral approach including the Ministries of Health, 
Education and Youth is crucial, besides working with 
communities on awareness and education of the population.  
Access to HIV care for HIV positive pregnant women is 
influenced by many factors. Having diagnostic tests for CD4+ 
T-cell count closer to care showed to lead to earlier initiation 
of treatment of HIV positive eligible pregnant women. This is 
important as suppression of viral load of HIV among pregnant 
women as soon as possible after diagnosis is crucial to decrease 
risk of transmission to the infant. However, having the 
necessary tests at the clinic does not always result in a higher 
uptake of ART initiation, indicating that other contextual 
factors play a role in uptake of treatment. Article 2 showed that 
having POC testing at the clinic did not increase uptake of 
testing. However, it decreased time to antiretroviral treatment 
initiation for HIV positive eligible women. Contextual factors 
play a role in uptake of testing and treatment, and need to be 
taken into consideration when plans for roll-out of rapid 
diagnostics are discussed.  
Factors influencing retention in postpartum PMTCT services 
for HIV positive pregnant and postpartum women and their 
infants were investigated in article 4. Barriers are mainly 
individual-level barriers where stigma, preference of 
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alternative care (outside the national health care services) and 
disbelief in the results are still important. What facilitates 
retention in services is having hope for a future for the child, 
presence of symptomatic illness and the belief that the health 
facility is the appropriate place for care.  
Male involvement in MCH and PMTCT care is important for 
prevention of infant HIV infection. This involvement starts 
with couple attendance at the first antenatal care visit and 
couple HIV testing. However, the study presented in article 1 
showed that knowledge of male partner testing is low: 19% of 
the women reported that their partner had been tested for 
HIV. Factors hindering the uptake of male HIV testing are fear 
of stigma and discrimination, but also the preconception of 
clinics being places for women. Having men attend ANC may 
not be the best viable strategy and reaching couples outside of 
the clinic may be necessary. 
There is a need for stronger linkages with the community, 
where decision makers are involved in health promotion 
activities. Continuous education and awareness are necessary.  
At institutional level, novel technologies embedded in 
existing services, new or re-organized health care services 
(such as male friendly health units, or family clinics) and 
task-shifting need to be tested to increase uptake and 
retention of MCH/PMTCT services, aiming at a decreased 
vertical transmission of HIV.  
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7.2. Samenvatting 
 
De Wereldgezondheidsorganisatie beveelt een alomvattende 
aanpak aan van de preventie van moeder-tot-kind transmissie 
van HIV bestaande uit vier onderdelen, namelijk: preventie van 
HIV-infectie bij vrouwen in de vruchtbare leeftijd; preventie 
van ongewenste zwangerschappen bij HIV-positieve vrouwen; 
zorg en behandeling van HIV-positieve zwangere vrouwen; 
nadruk op het gezin in plaats van op vrouw en kind alleen. 
Mozambique, gelegen in Sub-Saharisch Afrika, heeft een hoge 
HIV-prevalentie van 15.8% bij  zwangere vrouwen. Toen het 
preventieprogramma van moeder-op-kind transmissie in 2002 
van start ging, bestond de strategie uit het toedienen van één 
enkele dosis nevirapine, terwijl die vandaag bestaat uit een 
levenslange antiretrovirale behandelingvoor alle HIV-positieve 
vrouwen gediagnosticeerd tijdens zwangerschap en 
borstvoedingsperiode (Optie B+). 
In het proefschrift gebruikte een combinatie van kwantitatieve 
en kwalitatieve methoden om de aspecten van Mozambique’s 
programma te evalueren, zowel tijdens de prenatale als tijdens 
de postpartum periode. We onderzochten de risicofactoren 
voor HIV-besmetting tijdens zwangerschap en borstvoeding, 
en toegang tot preventie en behandeling voor HIV-positieve 
vrouwen en hun kinderen blootgesteld aan of geïnfecteerd met 
HIV. 
Zoals besproken in artikels 1 en 3 van de dissertatie, blijft de 
incidentie van HIV  hoog, zowel tijdens de zwangerschap als 
tijdens de postpartum periode (3.2 en 4.3 per 100 vrouwenjaren, 
respectievelijk), wat een verhoogd risico geeft op verticale 
transmissie. Eén van de acht HIV-besmettingen bij kinderen 
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wordt veroorzaakt door een acute HIV-infectie van de moeder 
tijdens borstvoeding. Risicofactoren voor het oplopen van HIV 
tijdens de kraamperiode zijn jonge leeftijd, lage pariteit, hoger 
onderwijsniveau van de partner, seksuele relaties met 
wisselende partners; gedurende de zwangerschap zijn de 
risicofactoren vroeg eerste seksueel contact en wonen in 
Maputo provincie. Strategieën van primaire preventie van HIV 
tijdens de zwangerschap en postpartumperiode moeten 
worden aangepastvoor deze subpopulatie, met een bijzondere 
aandacht voor jonge meisjes en vrouwen. Een multisectorale 
aanpak, met o.a. het Ministerie van Onderwijs, Ministerie van 
Jeugd, en Ministerie van Gezondheid is cruciaal, evenals het 
werken met de gemeenschappen aan bewustmaking en 
educatie van de bevolking.  
Toegang tot en retentie in programma’s ter preventie van 
moeder-kind transmissie van HIV hangt af van verscheidene 
factoren. Het plaatsen van de CD4+ T-cel telling in de kliniek 
in plaats van het laboratorium, dus dichter bij de 
patientenzorg, leidde tot een vroegere start van antiretrovirale 
behandeling. Dit is belangrijk omdat onderdrukking van de 
virale lading in zwangere vrouwen zo snel mogelijk na de 
diagnose cruciaal is om het risico van HIV-overdracht naar het 
kind te verminderen. Niettemin, de beschikbaarheid van de 
nodige tests in de kliniek resulteert niet altijd in een hoger 
aantal vrouwen die antiretrovirale behandeling starten, 
duidend op de rol van andere contextuele factoren. Artikel 2 
van de thesis toonde aan dat de aanwezigheid van ‘point-of-
care testing’ het aantal testen niet verhoogde, terwijl het wel 
de tijdspanne tussen diagnose en start van antiretrovirale 
therapie verkortte. Contextuele factoren spelen een rol bij het 
uitvoeren van testen en bij het instellen van behandeling. 
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Hiermee moet rekening worden gehouden bij discussies over 
het uitbreiden van toegang tot snelle diagnostische testen. 
Individuele, sociale, culturele en institutionele factoren 
beinvloeden de adherentie tot HIV diensten voor HIV-
positieve postpartum vrouwen en hun zuigelingen ), en 
werden onderzocht in artikel 4. Vrouwen voelen zich in de 
eerste plaats geremd op individueel niveau. Stigma, de 
voorkeur voor alternatieve zorg (buiten de traditionele 
medische voorzieningen) en het ongeloof in de resultaten 
spelen een belangrijke rol. Hoop voor een toekomst voor het 
kind, aanwezigheid van symptomatische ziekte en de 
overtuiging dat de (conventionele) gezondheidszorg 
doeltreffend is hebben dan weer een faciliterend effect.  
Betrokkenheid van mannelijke partners tot prenatale en 
postnatale zorgverlening en zorg ter preventie van moeder-tot-
kind transmissie van HIV is belangrijk voor de preventie van 
zuigeling HIV-infectie. Die betrokkenheid begint met de 
aanwezigheid van het koppel bij eerste prenataal consult en 
HIV-test voor het koppel. Kennis rond partner testing is echter 
laag, zoals beschreven in artikel 1: 19% van de vrouwen uit de 
cohorte vermeldden dat hun partner getest was voor HIV. Het 
is wellicht geen haalbare strategie om de partners bij  de 
prenatale zorgverlening te betrekken. Het bereiken van 
koppels buiten de gezondheidscentra is misschien 
noodzakelijk. Factoren die het testen van HIV bij mannen 
bemoeilijken zijn angst voor stigmatisering en discriminatie, 
en het vooroordeel dat de klinieken plaatsen zijn voor 
vrouwen. 
Een sterkere link met gemeenschappen is noodzakelijk, waar 
beleidsmakers betrokken zijn bij alle activiteiten rond 
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gezondheidspromotie. Continue opleiding en bewustwording 
zijn  nodig. Op institutioneel vlak zijn volgende alternatieven 
mogelijk:  introductie van nieuwe technologieën ingebed in de 
bestaande diensten, uitbouwen van nieuwe of  
gereorganiseerde diensten in de gezondheidszorg, zoals man-
vriendelijke of gezinsvriendelijke klinieken, verbetering van de 
organisatie van de zorgdiensten (delegatie van taken), zodat de 
toegang tot en opvolging in de verloskundige zorgverlening 
wordt verhoogd, met als  uiteindelijk doel de preventie van 
moeder-tot-kind transmissie van HIV tot een minimum te 
herleiden. 
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